Heartbeam, Inc. - Common Stock (BEAT)
0.7810
-0.8990 (-53.51%)
NASDAQ · Last Trade: Nov 22nd, 4:35 AM EST
Detailed Quote
| Previous Close | 1.680 |
|---|---|
| Open | 1.610 |
| Bid | 0.7400 |
| Ask | 0.7589 |
| Day's Range | 0.5400 - 1.630 |
| 52 Week Range | 0.5400 - 3.480 |
| Volume | 9,938,177 |
| Market Cap | 26.76M |
| PE Ratio (TTM) | 1.662 |
| EPS (TTM) | 0.5 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 510,042 |
Chart
About Heartbeam, Inc. - Common Stock (BEAT)
Heartbeam Inc is a healthcare technology company focused on developing innovative solutions for cardiac care. The company specializes in advanced heart monitoring technologies, particularly through its proprietary platform that combines telemedicine with electrocardiogram (ECG) technology. Heartbeam's products aim to provide healthcare professionals and patients with real-time monitoring and analysis of heart health, facilitating early detection of potential issues and improving patient outcomes. By leveraging cutting-edge technology, Heartbeam seeks to enhance the management of cardiovascular diseases and promote more informed healthcare decisions. Read More
News & Press Releases
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · November 21, 2025
The company said it will work with the agency to reach a resolution and expressed confidence in its clinical data.
Via Stocktwits · November 21, 2025
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Poised in the Future of Cardiac Care with Breakthrough Technology
HeartBeam (NASDAQ: BEAT) is on the verge of transforming how atrial fibrillation (“AF”) is detected and managed with its cable-free ECG technology. A recent article discussing this reads, “HeartBeam has developed a credit card-sized device and proprietary synthesis software that can capture heart signals in three dimensions and convert them into a full synthesized 12-lead ECG. By bringing clinical -grade cardiac diagnostics into the hands of patients wherever they are, HeartBeam is positioning itself at the forefront of a revolution in heart health, one that could greatly impact lives, reduce costs, and redefine the future of cardiac care.”
Via Investor Brand Network · November 19, 2025
NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Q3 2025 Results as FDA Review Nears Completion and Commercial Readiness Accelerates
HeartBeam (NASDAQ: BEAT) reported third-quarter 2025 results and highlighted continued progress toward commercialization of its 12-lead ECG synthesis software, now in the final stage of FDA 510(k) review with anticipated clearance by year end. The company is advancing commercial readiness, including a new partnership with HeartNexus for 24/7 cardiologist review services, alongside new scientific data presented at AHA Scientific Sessions and HRX Live 2025 and an expanded global IP portfolio of 24 issued patents. For the quarter, R&D expenses were $3.3 million, G&A expenses were $2.0 million, net loss was $5.3 million and cash totaled $1.9 million. HeartBeam will discuss its results and provide a business update during a conference call and webcast on Nov. 13 at 4:30 p.m. ET.
Via Investor Brand Network · November 14, 2025
HeartBeam reports Q3 2025 results, missing EPS estimates. The pre-revenue firm focuses on FDA clearance for its cardiac tech, a key milestone expected by year-end.
Via Chartmill · November 13, 2025
HeartBeam (BEAT) Q3 2025 Earnings Call Transcript
Via The Motley Fool · November 13, 2025
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operational results for the third quarter ended September 30, 2025.
By HeartBeam, Inc. · Via Business Wire · November 13, 2025
HeartBeam Inc. (NASDAQ: BEAT) Advances Remote Cardiac Diagnostics with HeartNexus Partnership
HeartBeam (NASDAQ: BEAT), a medical-technology company developing next-generation cardiac diagnostics via its patented 12-Lead ECG synthesis software, has announced a strategic collaboration with HeartNexus ( https://ibn.fm/yyz1i ). The partnership will expand access to cardiologist-level ECG insights for arrhythmia assessment anytime, anywhere. Cardiovascular disease remains the leading cause of mortality worldwide, responsible for an estimated 17.9 million deaths annually according to the World Health Organization ( https://ibn.fm/oQxTL ). ECGs are the most common cardiac test yet standard ECG testing often requires in-clinic visits, specialized…
Via Investor Brand Network · November 13, 2025
HeartBeam (NASDAQ: BEAT) has cemented its position as a vanguard in medical technology, earning multiple prestigious accolades that underscore its groundbreaking contributions to portable ECG innovation. Most notably, the company was recently identified as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest's "Total Cardiac Intelligence" report, placing it second worldwide in [...]
Via TokenRing AI · November 12, 2025
HeartBeam Inc. (NASDAQ: BEAT) Recognized as a Top Global Innovator in Portable ECG Technology
HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions for remote cardiac care, has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest’s “Total Cardiac Intelligence” report ( https://ibn.fm/ZuLCr ). The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. The recognition highlights HeartBeam’s growing influence in the next generation of cardiac monitoring technology.
Via Investor Brand Network · November 11, 2025
HeartBeam Inc. (NASDAQ: BEAT) Advances Toward Commercialization of Groundbreaking ECG System
In the world of heart health, palpitations are common, with atrial fibrillation (“AF”) being one of the most typical sustained arrhythmias in adults ( https://ibn.fm/8TSNY ). HeartBeam (NASDAQ: BEAT) is on the verge of transforming how AF is detected and managed with its breakthrough, cable-free ECG technology ( https://ibn.fm/B16MX ).
Via Investor Brand Network · November 6, 2025
AINewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Initiated With Buy Rating and $4 Price Target by Roth Capital
HeartBeam (NASDAQ: BEAT) has been initiated with a Buy rating and $4 price target by Roth Capital Partners, which highlighted the company’s near-term catalyst of expected FDA clearance for its groundbreaking 12-lead ECG synthesis software. The report cites BEAT’s compact, credit card-sized, cable-free device capable of synthesizing a full 12-lead ECG as a breakthrough in remote cardiac monitoring. Roth’s analysts, led by Kyle Bauser, Ph.D., view BEAT as undervalued given its strong clinical validation, lean cost structure, and potential to redefine how arrhythmias are detected and treated in decentralized care environments.
Via Investor Brand Network · November 5, 2025
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Schedules Third Quarter 2025 Conference Call for Nov. 13
HeartBeam (NASDAQ: BEAT), a medical technology company transforming cardiac care through personalized insights, will hold a conference call on Thursday, Nov. 13, 2025, at 4:30 p.m. ET to discuss its third quarter results for the period ended Sept. 30, 2025. The Company will also provide updates on regulatory progress, commercial-readiness activities, and upcoming milestones. A detailed press release will be issued prior to the call.
Via Investor Brand Network · October 30, 2025
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, November 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2025, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call.
By HeartBeam, Inc. · Via Business Wire · October 30, 2025
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Partners with HeartNexus to Deliver 24/7 Remote Cardiology Services and Real-Time ECG Interpretation
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, today announced a partnership with HeartNexus Inc., a network of board-certified cardiologists specializing in cardiac test interpretation, peer consultations, and telemedicine visits. The collaboration enables HeartBeam to offer 24/7 cardiology reader services for patients experiencing cardiac symptoms outside traditional care settings. Using HeartBeam’s patented 3D technology, patients can capture a 30-second, cable-free ECG recording anytime symptoms occur, transmitting the data to HeartNexus cardiologists for immediate interpretation. “Working with HeartNexus accelerates our mission to make medical-grade cardiac monitoring accessible beyond the walls of a medical facility,” said Robert Eno, CEO of HeartBeam. The partnership expands HeartBeam’s ecosystem with real-time cardiology feedback and future integration of AI wellness and wearable features.
Via Investor Brand Network · October 28, 2025
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced a partnership with HeartNexus, Inc., a network of board-certified cardiologists specializing in cardiac test interpretation, peer-to-peer consultations, and on-demand telemedicine visits.
By HeartBeam, Inc. · Via Business Wire · October 28, 2025
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Combining Portability and Precision to Redefine Future of Cardiac Care
HeartBeam (NASDAQ: BEAT) was featured in a recent article that discussed its development of a portable, credit-card-sized device and proprietary software capable of capturing heart signals in three non-coplanar dimensions and reconstructing those signals into a full synthesized 12-lead ECG. “The importance of such innovation is underscored by the widespread impact of heart disease, such as heart rhythm problems… The VALID-ECG study results carry significant weight for both clinical adoption and HeartBeam’s commercialization pathway,” reads the article. “For HeartBeam, the upcoming commercialization of its ECG system represents more than a regulatory milestone; it is a potential step toward redefining how heart disease is detected and treated. By combining portability with medical-grade accuracy, the company is creating a tool that could improve lives through earlier intervention, fewer hospitalizations and faster responses to arrhythmias. With study results validating its technology and commercialization plans advancing, HeartBeam stands poised not only to capture a significant market opportunity but also to play a vital role in the future of patient-centered cardiac care.”
Via Investor Brand Network · October 16, 2025
MissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) on the Beat of Cardiac Innovation
HeartBeam (NASDAQ: BEAT) is on the verge of revolutionizing cardiac diagnostics with its groundbreaking ECG technology. A recent article discussing this reads, “HeartBeam plans to initiate commercialization immediately upon receiving FDA clearance. The company’s vision is to empower patients and healthcare providers by offering a portable, cable-free ECG solution that combines clinical-grade accuracy with ease of use. This innovation is poised to reduce the burden on healthcare facilities, improve patient engagement, and increase the availability of high-quality cardiac monitoring, particularly in underserved areas or for patients requiring frequent arrhythmia assessments.”
Via Investor Brand Network · October 8, 2025
HeartBeam Inc. (NASDAQ: BEAT) Validates ECG Technology with Strong Results in Pivotal Study
Early and accurate detection of heart rhythm problems can mean the difference between life-saving intervention and a missed opportunity, which is why new advances in cardiac diagnostics carry such weight. HeartBeam (NASDAQ: BEAT) has reported promising results from its pivotal VALID-ECG study ( https://ibn.fm/BDiIa ), demonstrating that its synthesized 12-lead ECG technology delivers a strong correlation with the clinical gold standard of traditional 12-lead ECGs for non-life-threatening arrhythmias.
Via Investor Brand Network · October 7, 2025
NetworkNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) ECG System Offers Real-Time Cardiac Insights
HeartBeam (NASDAQ: BEAT) is positioned amid limitations of traditional 12-lead electrocardiogram (“ECG”) systems, often including cumbersome setups and restricted accessibility. The company “is addressing these challenges by developing the HeartBeam System, the first cable-free, high-fidelity ECG system that captures the heart’s electrical signals from three distinct directions and synthesizes the signals into a 12-lead ECG, enabling comprehensive arrhythmia assessment outside clinical settings. This innovative approach aims to revolutionize cardiac care by providing patients with the ability to monitor their heart health conveniently and accurately,” reads a recent article. “The HeartBeam System’s design emphasizes user friendliness and portability. The device is the size of a credit card, making it easy for patients to use at home or on the go. Patients can capture their ECG by placing the device on their chest for 30 seconds, after which the data is transmitted securely to an on-call cardiologist for review. This streamlined process enables timely interventions when necessary.”
Via Investor Brand Network · September 26, 2025
BioMedNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) First-of-Its-Kind Cable-Free ECG Offers Multi-Angle Signal Capture
As clinicians increasingly recognize the value of accurate at-home electrocardiogram (“ECG”) capture, HeartBeam (NASDAQ: BEAT) is positioned at the forefront of this transformation. The company’s FDA-cleared HeartBeam System is the first cable-free ECG device that captures the heart’s signals from three distinct directions and is designed to be a groundbreaking solution for at-home detection and monitoring of arrhythmias. “HeartBeam’s proprietary system allows for high-fidelity measurements without the complexity of conventional equipment. Unlike standard devices that capture electrical signals from limited perspectives, HeartBeam’s patented approach records from three distinct angles, enabling a more complete view of the heart’s electrical activity. This expanded data capture is intended to improve diagnostic precision, particularly for arrhythmias that may be missed with traditional methods. Additionally, the patient can always have the device with them and take a recording at the time of symptom onset, potentially reducing any delays in care.”
Via Investor Brand Network · September 22, 2025
HeartBeam Inc. (NASDAQ: BEAT) Prepares Innovative ECG Technology for Commercial Launch
In its most recent quarterly update, HeartBeam (NASDAQ: BEAT) is reporting that the company is on the verge of revolutionizing cardiac diagnostics with its groundbreaking ECG technology. The company is actively preparing for FDA 510(k) clearance of its innovative 12-lead ECG synthesis software for arrhythmia assessment while executing comprehensive commercial readiness plans for a technology that could transform how heart health is monitored both in clinical and home settings ( https://ibn.fm/dz7rY ).
Via Investor Brand Network · September 12, 2025
HeartBeam Inc. (NASDAQ: BEAT) Advances Power of ECG with High-Fidelity At-Home Heart-Monitoring System
For decades, the traditional 12-lead electrocardiogram (“ECG”) has been the gold standard in cardiac diagnostics, including arrhythmia assessment, offering a comprehensive assessment of the heart’s electrical activity. However, traditional 12-lead ECG systems often come with limitations such as cumbersome setups and restricted accessibility. HeartBeam (NASDAQ: BEAT) is addressing these challenges by developing the HeartBeam System, the first cable-free, high-fidelity ECG system that captures the heart’s electrical signals from three distinct directions and synthesizes the signals into a 12-lead ECG, enabling comprehensive arrhythmia assessment outside clinical settings. This innovative approach aims to revolutionize cardiac care by providing patients with the ability to monitor their heart health conveniently and accurately.
Via Investor Brand Network · September 10, 2025